Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 14 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Biontech SE maintains a portfolio with 16 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 15 distinct examiners, indicating a broad exposure to different individual examination styles. The workload is further spread across 13 distinct art units, which suggests a wide technical scope within the pharmaceutical sector. AEDER, SEAN E is the busiest examiner for the company, currently managing 2 pending actions.
The high number of 15 distinct examiners relative to 16 pending actions means that almost every case is being handled by a different individual. This lack of examiner concentration requires a highly individualized approach to each application rather than a unified strategy for a single examiner. With 13 distinct art units involved, the company must navigate various internal policies and technical standards at the USPTO. The concentration of 2 pending actions under examiner AEDER, SEAN E represents the highest workload for any individual official assigned to the 16 pending matters. Practitioners should be prepared for diverse feedback across this extensive list of administrative units.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (24%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 5 (29%) |
| Multi-statute (no §101) | 6 (35%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 2 | 56.9% | +20.0% |
| MISHRA, DEEPA | 1 | 28.9% | +35.5% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| ISKRA, JOSEPH W | 1 | 71.3% | +27.1% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | LI, RUIXIANG | 67d overdue |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | VAN BUREN, LAUREN K | 29d |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 55d |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | — |
| 18563738 | DEVICE AND METHOD FOR ACCELERATED THAWING | ISKRA, JOSEPH W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 4d overdue |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 26d |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | PERSONS, JENNA L | — |
| 18708333 | RNA ENCODING PEPTIDOGLYCAN HYDROLASE AND USE THEREOF FOR TREATING BACTERIAL INFECTION | ROBINSON, HOPE A | — |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | — |
| 18292232 | COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA | AEDER, SEAN E | — |
| 18570257 | COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS | METCALF, MATTHEW CURRAN | — |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| 1646 | 2 |
| 1642 | 2 |
| 1699 | 1 |
| 1652 | 1 |
| 1647 | 1 |
| 3781 | 1 |
| 1637 | 1 |
| 1636 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | 1657 | §102§112DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | PERSONS, JENNA L | 1699 | §103§112DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18708333 | RNA ENCODING PEPTIDOGLYCAN HYDROLASE AND USE THEREOF FOR TREATING BACTERIAL INFECTION | ROBINSON, HOPE A | 1652 | §112 | Final Rejection | — | Pending | May 08, 2024 |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18292232 | COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA | AEDER, SEAN E | 1642 | §103DP | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18570257 | COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS | METCALF, MATTHEW CURRAN | 1647 | §103§112DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18563738 | DEVICE AND METHOD FOR ACCELERATED THAWING | ISKRA, JOSEPH W | 3781 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 1646 | — | Final Rejection | 26d | Pending | Jun 20, 2023 |
| 18268124 | THERAPEUTIC RNA FOR TREATING CANCER | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Final Rejection | 4d overdue | Pending | Jun 16, 2023 |
| 18266135 | RNA MANUFACTURING | ZAHORIK, AMANDA MARY | 1636 | §103Other | Final Rejection | — | Pending | Jun 08, 2023 |
| 18035172 | MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE | SKELDING, ZACHARY S | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 03, 2023 |
| 18134844 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | HADDAD, MAHER M | 1641 | §103Other | Final Rejection | 70d | Pending | Apr 14, 2023 |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | VAN BUREN, LAUREN K | 1638 | §103§112 | Final Rejection | 29d | Pending | Mar 10, 2023 |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 3736 | §103§112 | Final Rejection | 55d | Pending | Oct 21, 2022 |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | LI, RUIXIANG | 1674 | §103§112 | Final Rejection | 67d overdue | Pending | Sep 29, 2022 |
| 17609358 | NOVEL GARDNERELLA ENDOLYSINS AND USES THEREOF | EDWARDS, JESSICA FAYE | 1657 | §103 | Final Rejection | — | Pending | Nov 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiontech SE has 17 pending office actions as of October 2026, spread across 14 art units and 16 examiners.
Sean E Aeder has the most, with 2 of Biontech SE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
